NIH Reopens the Kids First Sequencing Contract: $6 Million a Year for One or Two Genomic Data Generation Centers

Since 2016, the work of sequencing samples for the Gabriella Miller Kids First Pediatric Research Program has gone to two institutions: the Broad Institute and the HudsonAlpha Institute for Biotechnology. Three NIH funding notices have rewarded the same pair, and the most recent one, in 2021, was a limited competition. On October 29, 2026, NIH posted the next one.

RFA-RM-27-008, "Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)," will fund one or two sequencing centers for up to three years. The NIH Common Fund "intends to commit $5-6M per year," and each award "may not exceed $3.5M per year in direct costs." Grants.gov lists total program funding of $6,000,000. Submissions open December 8, 2026, and applications are due January 8, 2027, at 5:00 p.m. local time. NIH accepts no late applications.

The title does not say limited competition this time. Any qualified sequencing operation in the United States can bid, including universities, independent research institutes, nonprofits, and for-profit genomics companies. It is one of the few times this decade that a long-running NIH data-production contract has been open to new bidders.

What Kids First Is, and Why the Sequencing Center Matters

Congress created Kids First through the Gabriella Miller Kids First Research Act (H.R. 2019, 113th Congress). The law is named for a 10-year-old from Leesburg, Virginia, who died of an inoperable brain tumor in 2013. The NOFO says the program ran "for an initial 10 years, from 2015-2024," and was "reauthorized as Kids First 2.0 by the 118th Congress for an additional five years." The program has since moved organizationally from the Common Fund into NIH's Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), but the Common Fund still runs it. NICHD manages the award.

The design has three parts:

1. Investigators apply through a series of X01 funding notices to have their existing pediatric cohorts sequenced. Their specimens come from children with childhood cancers, structural birth defects, or both. These notices have run almost every year since PAR-15-259, most recently PAR-24-082.
2. Sequencing centers, the role RFA-RM-27-008 now re-competes, receive the specimens and turn them into genomes.
3. The Kids First Data Resource Center (DRC) reprocesses and harmonizes the output and serves it to the research community through a controlled-access portal.

Researchers who win X01s do not pay for sequencing. NIH pays the centers directly, which makes the center award the main cost line for the program's data production. According to the Kids First program page, the program has released "nearly 30,000 genomes" and the clinical and genetic data from 36 of its projects. The NOFO puts current demand at "approximately 6,000-10,000 samples per year."

The center also sets the standard for the data. File formats, QC thresholds, turnaround time, and how quickly new assays come online all start with the center and carry through the DRC to every researcher who later uses a Kids First dataset.

Reading the Budget: Why "One or Two" Matters

The budget figures limit what a winning proposal can look like.

A single center budgeted at the $3.5 million direct-cost ceiling would cost roughly $5 million to $6 million a year once facilities and administrative (F&A) costs are added at typical negotiated rates. That uses up nearly all of the Common Fund's stated $5-6M annual commitment. Two centers at the ceiling would need $7 million in direct costs alone, more than the whole envelope.

Two awards are therefore only possible if each comes in well under the cap, at about $2-2.5 million in direct costs, or if one applicant has low or no indirect costs. An applicant can take one of three approaches:

• The full-service bid. Budget near the ceiling, offer to handle all of the 6,000-10,000-sample annual volume, and compete to be the only center. This suits large genome centers with existing NIH production contracts.
• The partner bid. Budget at roughly half the envelope and present the center as a second source, offering surge capacity, a specialty assay (long reads, RNA-seq, methylation), or geographic redundancy. This is the more realistic route for a new entrant, but it only works if NIH chooses to make two awards.
• The cost-curve bid. The NOFO says throughput and cost should improve over the award period without loss of quality, and it requires a cost reduction plan. An applicant with a credible plan to cut per-genome cost in years two and three can offer more samples for the same money. That is the case reviewers will judge.

The required budget section, Research Plan section C, asks for per-sample costs for each data type, the total sample count, and the cost reduction plan. Reviewers will compare these numbers across applicants. A vague number will lose to a specific one.

What Reviewers Will Score

RFA-RM-27-008 uses the standard NIH criteria: Significance, Investigator(s), Innovation, Approach, and Environment, combined into an overall impact score. The notice adds to them in ways that show what NIH wants.

Speed on new assays. Under Innovation, reviewers will consider whether the center can implement new assays quickly, "e.g., within 2 months." Kids First started with whole-genome sequencing of trios, and cohort investigators increasingly ask for transcriptomic, long-read, and other data types. A center that needs a year to validate a new protocol does not fit what the program now needs.

Family-based designs. Applicants must estimate a minimum sample count assuming equal numbers of trios and quads. The program studies affected children together with their parents and siblings, so the proposal should show experience handling linked family samples, including pedigree checks and sample-swap detection.

Hand-off to the DRC. Research Plan section E must describe how the center will coordinate with the Data Resource Center. It needs to cover sample-level tracking, data transfer, and standard formats such as BAM/CRAM aligned to GRCh38 and VCF. Centers must deliver "individual-level sequences, derived data, and metadata" to the DRC and to the investigators who own the samples. The specimen intake section, Research Plan section A, requires sample and subject IDs "two-steps removed from personal information per dbGaP requirements," along with documented QC, DNA extraction, pipelines, and IT security.

Data retention. Section B covers computational capacity. The center must store data "for at least one year after data generation completes," so storage costs belong in the budget.

The application also needs a Data Management and Sharing Plan on the NIH format page and a Resource Sharing Plan. Neither is scored, but both have to be acceptable before NIH will fund the award.

Eligibility, and a Discrepancy to Watch

The eligible applicant list is broad. It includes public and private higher education institutions, nonprofits with or without 501(c)(3) status, small businesses and other for-profits, state and local governments, and federally recognized tribal governments. Commercial genomics service providers are eligible to compete for this money.

The Grants.gov "Other Eligible Applicants" field lists non-domestic entities. The NOFO itself says that "Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply." It also excludes non-domestic components of U.S. organizations and foreign components. The NOFO controls. A foreign sequencing provider can take part only as a vendor in a way NIH policy allows, and should not plan around the Grants.gov listing.

Organizations may submit more than one application if they are "scientifically distinct." Clinical trials are not allowed, but human subjects research that is not a clinical trial is. Every PI needs an eRA Commons account linked to an ORCID iD, and SAM registrations must be current. Allow several weeks for SAM, because applications are due right after the holidays.

The Timeline and the Strategy Around It

There is no letter of intent, so NIH will not learn who is competing before applications arrive. The program contact, kidsfirst@od.nih.gov, is the only way to ask questions before then. Applicants should use it, especially about whether NIH wants one center or two. The answer determines which budget approach makes sense.

For the incumbents, the risk is complacency. Reviewers who see an open competition after three rounds won by the same pair may reward a challenger with a sharper cost curve or faster assay adoption. The incumbents' strongest case is concrete performance data: turnaround times, QC pass rates, and per-genome cost trends since 2021.

For challengers, including academic genome centers, cancer-center sequencing cores, and CLIA-certified commercial labs, the opening is real but narrow. A credible bid needs documented production at the scale of thousands of genomes, a pediatric or family-based track record, and letters showing how the DRC interface would work from the first day. A core facility that has never delivered more than a few hundred genomes a year should look for a partner bid with a larger operation, not apply alone.

For cohort investigators, this notice does not fund their work, but it affects them. The sequencing center chosen in 2027 will process X01 cohorts through 2030. Investigators planning an X01 application should watch which assays the winning center offers.

Applicants who want help turning a sequencing operation's performance record into a competitive U24 narrative can use Granted to draft and pressure-test each research plan section before the January 8 deadline.